What Can We Learn From Evaxion Biotech A/S (EVAX)’s Valuation Ratios?

0
5
BEPC Stock
BEPC Stock

Evaxion Biotech A/S (NASDAQ:EVAX) finished Wednesday with an addition of $0.43 to close at $2.33, an upside of 22.63 percent. An average of 9,244,940 shares of common stock have been traded in the last five days. There was a gain of $0.2800 in the past week, and it reached a new high 5 times over the past 12 months. The last 20 days have seen an average of 2,327,930 shares traded, while the 50-day average volume stands at 953,692.

EVAX stock has decreased by -13.70% in the last month. The company shares reached their 1-month lowest point of $1.9000 on 09/20/22. With the stock rallying to its 52-week high on 01/06/22, shares of the company touched a low of $1.51 and a high of $25.04 in 52 weeks. It has reached a new high 3 times so far this year and lost -47.29% or -$2.0900 in price. In spite of this, the price is down -90.69% from the 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Financial Health

The quick ratio of Evaxion Biotech A/S for the three months ended June 29 was 6.50, and the current ratio was 6.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.46 and a total debt to equity ratio of 0.48 for the quarter ending June 29. Its gross profit as reported stood at $0.92 million compared to revenue of $25.83 million.

Earnings Surprise

For the three-month period that ended June 29, Evaxion Biotech A/S had $0.84 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$24.53 million in the quarter, while revenues were grew 38.77%. The analyst consensus anticipated Evaxion Biotech A/S’s latest quarter earnings to come in at -$0.3 per share, but it turned out to be -$0.2, a 33.30% surprise. For the quarter, EBITDA amounted to -$6.26 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Evaxion Biotech A/S (EVAX) price momentum. RSI 9-day as of the close on 21 September was 59.71%, suggesting the stock is Neutral, with historical volatility in this time frame at 110.30%.

As of today, EVAX’s price is $2.0600 +13.66% or $0.2800 from its 5-day moving average. EVAX is currently trading -12.41% lower than its 20-day SMA and -23.36% lower than its 100-day SMA. However, the stock’s current price level is +4.02% above the SMA50 and -44.12% below the SMA200.

The stochastic %K and %D were 16.50% and 14.97%, respectively, and the average true range (ATR) was 0.3300. With the 14-day stochastic at 26.54% and the average true range at 0.2900, the RSI (14) stands at 52.50%. The stock has reached 0.0100 on the 9-day MACD Oscillator while the 14-day reading was at -0.0200.

LEAVE A REPLY

Please enter your comment!
Please enter your name here